Dr. Yipeng Wang 王一澎
Chief Physician
Department of Breast Surgery, Cancer Hospital, Chinese Academy of Medical Sciences (National Cancer Center), Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Individualized and standardized surgery for breast tumors, including modified radical mastectomy, breast-conserving surgery, and axillary-sparing procedures. Treatment of complex breast cancer cases and postoperative breast reconstruction using expanders, implants, latissimus dorsi, or rectus abdominis flaps.
Dr. Wang holds a doctorate in oncology from Peking Union Medical College and has practiced breast tumor surgery for 20 years. Dr. Wang studied clinical surgery and diagnostic techniques at the MD Anderson Cancer Center in the United States.
Professional roles
- Member of the editorial and review group for the Ministry of Health's 'Standardized Diagnosis and Treatment of Breast Cancer'
Name order: in Chinese the family name comes first (Wang Yipeng). Papers usually list the name as Yipeng Wang or Wang Y.
Selected publications
29 papers on PubMed matched by name and affiliation; 12 as first or senior author since 2016. Most recent first- or senior-author papers:
- Acta Psychol (Amst), 2026 (senior author): MIDAS: A multimodal interview-based framework for depression assessment from clinical interviews. PubMed 42664926
- Aesthetic Plast Surg, 2026 (senior author): Application of Titanium-Coated Polypropylene Mesh (TiLOOP Bra) Combined with a De-Epithelialized Dermal Flap During Skin-Reducing Mastectomy (SRM) for Immediate Implant-Based Breast Reconstruction (IBR) in Chinese Patients. PubMed 41361148
- Cancer Control, 2026 (senior author): Exploring the Impact of Time to Surgery Following Different Biopsy Techniques on Early Breast Cancer Prognosis: A Retrospective Study From a Center in China. PubMed 42878221
- Clin Breast Cancer, 2024 (senior author): The Impact of Neoadjuvant Chemotherapy on Patients With T1N0M0 Triple-Negative and HER-2 Positive Breast Cancer: A Retrospective Analysis Based on the SEER Database. PubMed 38890023
- Target Oncol, 2024 (senior author): Prognostic Impact of HER2-Low and HER2-Zero in Resectable Breast Cancer with Different Hormone Receptor Status: A Landmark Analysis of Real-World Data from the National Cancer Center of China. PubMed 38265547
- Future Oncol, 2023 (senior author): Occult breast cancer patients with mastectomy have better prognosis than those with breast-conserving therapy. PubMed 38018520
- Front Oncol, 2023 (senior author): Identifying clinicopathological risk factors for regional lymph node metastasis in Chinese patients with T1 breast cancer: a population-based study. PubMed 37601676
- JAMA Netw Open, 2023 (senior author): Clinical Features and Prognoses of Patients With Breast Cancer Who Underwent Surgery. PubMed 37624596
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion